Foghorn Therapeutics (FHTX) Current Leases (2019 - 2026)

Foghorn Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Current Leases fell 79.56% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 79.56% decrease from a year earlier, with the FY2025 full-year figure at $923000.0, down 89.82% from the prior year.
• Current Leases grew to $1.9 million in Q1 2026 per FHTX's latest filing, from $923000.0 in the prior quarter.
• Across five years, Current Leases topped out at $9.1 million in Q1 2025 and bottomed at $923000.0 in Q4 2025.
• The 5-year median for Current Leases is $6.8 million (2025), against an average of $6.8 million.
• Across the five-year window, Current Leases surged 42.68% in 2023 and slumped 89.82% in 2025, its largest moves.
• Year by year, Current Leases stood at $6.0 million in 2022, then soared by 42.68% to $8.5 million in 2023, then grew by 6.45% to $9.1 million in 2024, then slumped by 89.82% to $923000.0 in 2025, then jumped by 101.84% to $1.9 million in 2026.
• Per Business Quant, the three latest FHTX Current Leases figures stand at $1.9 million (Q1 2026), $923000.0 (Q4 2025), and $6.8 million (Q3 2025).